Table 1.
An Illustrative List of Approved Anti-Cancer Drugs that are discussed in this review.
| No. | Drug Name | Active Ingredients | Company | Target | FDA Approval Date | Clinical Applications |
|---|---|---|---|---|---|---|
| 1 | Piqray | Alpelisib | Novartis | PI3K | May 24, 2019 | To treat breast cancer |
| 2 | Enhertu | Fam-trastuzumab deruxtecan-nxki | Daiichi Sankyo Company Ltd. and AstraZeneca | HER2 | December 20, 2019 | |
| 3 | Tukysa | Tucatinib | Array BioPharma | HER2 and HER3 | April 17, 2020 | |
| 4 | Trodelvy | Sacituzumab govitecan-hziy | Immunomedics | Topoisomerase I inhibitor | April 22, 2020 | |
| 5 | Rozlytrek | Entrectinib | Genentech, Inc. | NTRK | August 15, 2019 | To treat patients with NSCLC |
| 6 | Tabrecta | Capmatinib | Novartis Oncology | c-Met/HGFR | May 6, 2020 | |
| 7 | Gavreto | Pralsetinib | Blueprint Medicines Corporation | RET | September 04, 2020 | |
| 8 | Tepmetko | Tepotinib | Merck | MET exon 14 skipping mutations | March 25, 2020 | |
| 9 | Exkivity | Mobocertinib | Takeda Pharmaceutical Company Limited | EGFR | September 15, 2021 | |
| 10 | Zepzelca | Lurbinectedin | Pharma Mar, S.A. | Alkylating drug | June 15, 2020 | To treat patients with SCLC |
| 11 | Cosela | Trilaciclib | G1 Therapeutics | CDK4 and CDK6 | February 12, 2021 | |
| 12 | Nubeqa | Darolutamide | Orion and Bayer | Androgen receptor (AR) andprogesterone receptor (PR) | July 30, 2019 | To treat patients with prostate cancer |
| 13 | Orgovyx | Relugolix | Myovant Sciences | GnRH | December 18, 2020 | |
| 14 | Lumakras | Sotorasib | Amgen | KARSG12C | March 28, 2021 | To treat patients with Ovarian cancer |
| 15 | Cytalux | Pafolacianine | On Target Laboratories, Inc. | Folate receptors | November 29, 2021 | To detect ovarian cancer lesions |
| 16 | Retevmo | Selpercatinib | Loxo Oncology | VEGFR1 and VEGFR3 | May 08, 2020 | Use in the treatment of Lung and Thyroid Cancers |
| 17 | Ayvakit | Avapritinib | Blueprint Medicines Corporation | PDGFRA, PDGFRA D842 mutants, KIT exon 11, 11/17 and 17 mutants | January 09, 2020 under | To treat patients with GIST |
| 18 | Qinlock | Ripretinib | Deciphera Pharmaceuticals, Inc. | KIT and PDGFRA mutants | May 15, 2020 | |
| 19 | Fotivda | Tivozanib | AVEO Oncology | VEGFR-1, VEGFR-2 and VEGFR-3 | March 10, 2021 | To treat patients with renal cell carcinoma |
| 20 | Balversa | Erdafitinib | Janssen Pharmaceutical Companies | FGFR1, 2, 3 and 4 | April 12, 2019 | To treat patients with Bladder cancer |
| 21 | Padcev | Enfortumab vedotin-ejfv | Astellas Pharma Support SolutionsSM | Nectin-4-expressing cells | December 13, 2019 | |
| 22 | Polivy | Polatuzumab vedotin-piiq | Genentech | CD79b | June 10, 2019 | To treat patients with lymphoma |
| 23 | Brukinsa | Zanubrutinib | BeiGene | Cysteine residue in Bruton tyrosine kinase (BTK) active site | November 14, 2019 | |
| 24 | Ukoniq | Umbralisib | TG Therapeutics | PI3Kδ and CK1ε kinase | February 5, 2021 | |
| 25 | Xpovio | Selinexor | Karyopharm Therapeutics | XPO1 inhibitor | July 03, 2019 | To treat patients with Myeloma |
| 26 | Blenrep | Belantamab mafodotin-blmf | GlaxoSmithKline | BCMA | August 05, 2020 | |
| 27 | Pemazyre | Pemigatinib | Incyte Corporation | FGFR1, FGFR2, FGFR3 and FGFR4 | April 17, 2020 | To treat adult patients with cholangiocarcinoma |
| 28 | Tazverik | Tazemetostat | Epizyme, in collaboration with Eisai | EZH2 | January 23, 2020 | To treat patients with epithelioid sarcoma |
| 29 | Inrebic | Fedratinib | Celgene Corporation | JAK2 | August 16, 2019 | To treat patients with myelofibrosis |
| 30 | Inqovi | Decitabine, andCedazuridine | Astex Pharmaceuticals | Nucleoside metabolic inhibitor | July 7, 2020 | To treat patients with MDS |
| 31 | Koselugo | Selumetinib | AstraZeneca | MEK1/2 | April 10, 2020 | To treat patients with NF1 |
| 32 | Pylarify | Piflufolastat F 18 | Progenics Pharmaceuticals Inc. | PSMA | May 27, 2021 | Diagnosis of prostate cancer |
| 33 | Ga-68-DOTATOC | Ga-68-DOTATOC | Evergreen Theragnostics, Inc. | Somatostatin receptors | August 21, 2019 | Diagnosis of NETs |
| 34 | Detectnet | Copper Cu-64 Dotatate Injection | RadioMedix, and Curium | somatostatin receptors | September 03, 2020 |